TG Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -2.86%428.050.0%$5858.73m
BNTXBioNTech SE -4.46%356.040.0%$1226.70m
NVAXNovavax, Inc. -1.81%232.9779.4%$922.32m
SNSSSunesis Pharmaceuticals, Inc. 0.12%8.530.7%$596.28m
AMGNAmgen, Inc. 0.18%217.741.4%$528.85m
REGNRegeneron Pharmaceuticals, Inc. -1.13%645.772.7%$516.85m
GILDGilead Sciences, Inc. -0.59%70.911.0%$419.14m
ILMNIllumina, Inc. -0.49%447.713.5%$378.24m
TECHBio-Techne Corp. 1.05%535.004.5%$331.75m
BIIBBiogen, Inc. -0.45%298.341.7%$291.47m
VRTXVertex Pharmaceuticals, Inc. -0.17%186.791.9%$230.18m
ISEEIVERIC bio, Inc. -1.83%16.060.0%$185.66m
BGNEBeiGene Ltd. 4.29%401.781.3%$166.24m
LIFEaTyr Pharma, Inc. -6.14%9.633.2%$130.77m
KDMNKadmon Holdings, Inc. -0.74%8.760.9%$127.22m

Company Profile

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.